vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Local Bounti Corporation (LOCL). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $12.5M, roughly 1.5× Local Bounti Corporation). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -69.8%, a 69.0% gap on every dollar of revenue. On growth, Local Bounti Corporation posted the faster year-over-year revenue change (23.7% vs -25.7%). Local Bounti Corporation produced more free cash flow last quarter ($-3.6M vs $-15.8M). Over the past eight quarters, Local Bounti Corporation's revenue compounded faster (21.9% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Local Bounti Corporation is a U.S.-based sustainable indoor agriculture firm growing fresh, pesticide-free leafy greens, herbs and produce via advanced hydroponic and vertical farming tech. It serves North American retail and food service partners, focusing on low environmental impact and stable year-round supply.
CTMX vs LOCL — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $12.5M |
| Net Profit | $-154.0K | $-8.7M |
| Gross Margin | — | 12.2% |
| Operating Margin | -6.9% | -106.1% |
| Net Margin | -0.8% | -69.8% |
| Revenue YoY | -25.7% | 23.7% |
| Net Profit YoY | 97.6% | 76.0% |
| EPS (diluted) | — | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.5M | ||
| Q3 25 | — | $12.2M | ||
| Q2 25 | $18.7M | $12.1M | ||
| Q1 25 | $50.9M | $11.6M | ||
| Q4 24 | $38.1M | $10.1M | ||
| Q3 24 | $33.4M | $10.2M | ||
| Q2 24 | $25.1M | $9.4M | ||
| Q1 24 | $41.5M | $8.4M |
| Q4 25 | — | $-8.7M | ||
| Q3 25 | — | $-26.4M | ||
| Q2 25 | $-154.0K | $-21.6M | ||
| Q1 25 | $23.5M | $-37.7M | ||
| Q4 24 | $18.9M | $-36.3M | ||
| Q3 24 | $5.7M | $-34.3M | ||
| Q2 24 | $-6.5M | $-25.3M | ||
| Q1 24 | $13.8M | $-24.1M |
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | — | 12.2% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.4% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 14.3% | ||
| Q1 24 | — | 9.4% |
| Q4 25 | — | -106.1% | ||
| Q3 25 | — | -149.4% | ||
| Q2 25 | -6.9% | -127.7% | ||
| Q1 25 | 44.4% | -135.6% | ||
| Q4 24 | 46.4% | -166.6% | ||
| Q3 24 | 12.3% | -176.0% | ||
| Q2 24 | -33.7% | -146.8% | ||
| Q1 24 | 28.1% | -122.9% |
| Q4 25 | — | -69.8% | ||
| Q3 25 | — | -216.6% | ||
| Q2 25 | -0.8% | -178.3% | ||
| Q1 25 | 46.2% | -324.6% | ||
| Q4 24 | 49.6% | -360.1% | ||
| Q3 24 | 17.2% | -335.2% | ||
| Q2 24 | -26.0% | -267.6% | ||
| Q1 24 | 33.3% | -286.9% |
| Q4 25 | — | $1.52 | ||
| Q3 25 | — | $-1.18 | ||
| Q2 25 | — | $-1.63 | ||
| Q1 25 | — | $-4.32 | ||
| Q4 24 | — | $-4.24 | ||
| Q3 24 | — | $-4.01 | ||
| Q2 24 | — | $-3.00 | ||
| Q1 24 | — | $-2.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $4.2M |
| Total DebtLower is stronger | — | $483.1M |
| Stockholders' EquityBook value | $119.9M | $-166.2M |
| Total Assets | $175.1M | $410.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.2M | ||
| Q3 25 | — | $6.2M | ||
| Q2 25 | $49.0M | $5.3M | ||
| Q1 25 | $47.6M | $18.0M | ||
| Q4 24 | $38.1M | $937.0K | ||
| Q3 24 | $40.6M | $317.0K | ||
| Q2 24 | $43.2M | $9.7M | ||
| Q1 24 | $36.2M | $8.2M |
| Q4 25 | — | $483.1M | ||
| Q3 25 | — | $484.9M | ||
| Q2 25 | — | $478.3M | ||
| Q1 25 | — | $480.0M | ||
| Q4 24 | — | $436.8M | ||
| Q3 24 | — | $398.4M | ||
| Q2 24 | — | $374.0M | ||
| Q1 24 | — | $329.8M |
| Q4 25 | — | $-166.2M | ||
| Q3 25 | — | $-158.1M | ||
| Q2 25 | $119.9M | $-132.7M | ||
| Q1 25 | $25.0M | $-134.5M | ||
| Q4 24 | $-456.0K | $-100.5M | ||
| Q3 24 | $-23.5M | $-65.6M | ||
| Q2 24 | $-31.2M | $-32.8M | ||
| Q1 24 | $-31.7M | $-9.4M |
| Q4 25 | — | $410.5M | ||
| Q3 25 | — | $417.8M | ||
| Q2 25 | $175.1M | $426.8M | ||
| Q1 25 | $98.5M | $447.2M | ||
| Q4 24 | $120.5M | $428.0M | ||
| Q3 24 | $139.0M | $430.8M | ||
| Q2 24 | $159.2M | $438.1M | ||
| Q1 24 | $184.7M | $413.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-3.1M |
| Free Cash FlowOCF − Capex | $-15.8M | $-3.6M |
| FCF MarginFCF / Revenue | -84.6% | -29.1% |
| Capex IntensityCapex / Revenue | 0.1% | 3.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-42.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-3.1M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | $-15.8M | $-8.7M | ||
| Q1 25 | $-21.0M | $-9.6M | ||
| Q4 24 | $-19.9M | $1.2M | ||
| Q3 24 | $-20.7M | $-17.2M | ||
| Q2 24 | $-19.5M | $-4.0M | ||
| Q1 24 | $-26.0M | $-7.1M |
| Q4 25 | — | $-3.6M | ||
| Q3 25 | — | $-10.1M | ||
| Q2 25 | $-15.8M | $-14.6M | ||
| Q1 25 | $-21.2M | $-14.5M | ||
| Q4 24 | $-20.0M | $-8.6M | ||
| Q3 24 | $-20.7M | $-30.0M | ||
| Q2 24 | $-19.6M | $-28.8M | ||
| Q1 24 | $-26.2M | $-42.1M |
| Q4 25 | — | -29.1% | ||
| Q3 25 | — | -82.8% | ||
| Q2 25 | -84.6% | -121.0% | ||
| Q1 25 | -41.6% | -125.1% | ||
| Q4 24 | -52.5% | -85.3% | ||
| Q3 24 | -62.1% | -293.1% | ||
| Q2 24 | -78.2% | -305.4% | ||
| Q1 24 | -63.1% | -501.8% |
| Q4 25 | — | 3.9% | ||
| Q3 25 | — | 9.7% | ||
| Q2 25 | 0.1% | 48.9% | ||
| Q1 25 | 0.2% | 42.8% | ||
| Q4 24 | 0.2% | 97.6% | ||
| Q3 24 | 0.1% | 125.0% | ||
| Q2 24 | 0.4% | 263.0% | ||
| Q1 24 | 0.3% | 417.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
LOCL
Segment breakdown not available.
